ATC Group: B03XA07 Daprodustat

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B03XA07 in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B03 Antianemic preparations
3 B03X Other antianemic preparations
4 B03XA Other antianemic preparations
5 B03XA07

Active ingredients in B03XA07

Active Ingredient Description
Daprodustat

Daprodustat is indicated for the treatment of anemia due to chronic kidney disease. Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC50 in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.

Related product monographs

Title Information Source Document Type  
JESDUVROQ Film coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Japan (JP)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.